Abstract
Background Pulmonary physiotherapy (PPT) is an important therapeutic tool in the management of patients with different types of pulmonary disorders. We aimed to evaluate safety and efficacy of PPT in hospitalized patients with severe COVID-19 pneumonia.
Methods In this randomised, single-blind, controlled trial, we enrolled hospitalized, non-intubated patients (18 to 75 years with oxygen saturation(Spo2) in free-air breathing ≤90%) with COVID-19 pneumonia at a referral hospital. Participants were randomly assigned(1:1) to receive PPT (six sessions PPT with breathing exercises and airway clearance techniques) or basic care. The primary outcomes were venous blood O2(pO2) and CO2(pCO2) pressures, Spo2, and three-minute walking test(3MWT) that were assessed before and end of sixth session. Secondary outcomes included level of dyspnea, venous blood PH, one-month mortality, three-month mortality and short form-36 (SF-36) after one and three months. The assessor was blinded to the assignment. This trial is registered with ClinicalTrials.gov(NCT04357340).
Findings In April 2020, 40 participants were randomly assigned to PPT or basic care groups. At the end of intervention, pO2mortality rates wererence to baseline measure(AMD) 6.43mmHg [95%CI 2.8,10.07],P<0.0001), pCO2(AMD -2.1mmHg [95%CI-6.36,2.21],P=0.0011), Spo2(AMD 4.43% [95%CI 2.04,6.83],P=0.0011), and 3MTW (AMD 91.44m [95%CI 68.88,113.99],P<0.0001) were different between groups. While the mortality rate was not different at one month, at three months it was 25% lower in the PPT group (P=.05). This result needs to be reviewed overall though within the manuscript as it is also reported as insignificant “after considering baseline Spo2 as a covariate: OR=.16 [.26,1.05], P=.07;table 4). There were no significant difference in all SF-36 domains scores between groups after one and three months except body pain domain which was higher in PPT group than basic group significantly(P=.01). No serious adverse event was observed during PPT sessions.
Conclusion Early PPT can be considered as a safe and effective therapeutic choice for patients with severe COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04357340
Funding Statement
This study was funded by the Tehran University of Medical Sciences. The founder of the study had no role in study design, data collection, analysis, interpretation, or writing the manuscript. The corresponding author had full access to all the data in the study and is responsible for publishing the results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Committee of Imam Khomeini Hospital Complex, Tehran University of Medical Sciences
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.